BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,037 filers reported holding BAXTER INTL INC in Q1 2015. The put-call ratio across all filers is 0.65 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $42,223,000 | +5.0% | 952,247 | +12.7% | 0.14% | +1.5% |
| Q3 2016 | $40,225,000 | +11.6% | 845,069 | +6.0% | 0.14% | +6.2% |
| Q2 2016 | $36,049,000 | +20.3% | 797,195 | +9.3% | 0.13% | +15.2% |
| Q1 2016 | $29,968,000 | +11.7% | 729,492 | +3.7% | 0.11% | +12.0% |
| Q4 2015 | $26,831,000 | +16.5% | 703,295 | +0.3% | 0.10% | +8.7% |
| Q3 2015 | $23,023,000 | -61.2% | 700,849 | -17.5% | 0.09% | -59.8% |
| Q2 2015 | $59,380,000 | +34.8% | 849,129 | +32.0% | 0.23% | +30.1% |
| Q1 2015 | $44,050,000 | -34.3% | 643,062 | -29.7% | 0.18% | -31.5% |
| Q4 2014 | $67,073,000 | -3.6% | 915,174 | -5.6% | 0.26% | -14.3% |
| Q3 2014 | $69,553,000 | +3.4% | 969,106 | +4.1% | 0.30% | -2.3% |
| Q2 2014 | $67,280,000 | +4.9% | 930,565 | +6.7% | 0.31% | +7.3% |
| Q1 2014 | $64,145,000 | +9.9% | 871,776 | +3.9% | 0.29% | +10.4% |
| Q4 2013 | $58,380,000 | +15.8% | 839,402 | +9.4% | 0.26% | +7.9% |
| Q3 2013 | $50,404,000 | -25.9% | 767,299 | -21.8% | 0.24% | -23.3% |
| Q2 2013 | $67,982,000 | – | 981,404 | – | 0.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 36,000,000 | $2,658,240,000 | 18.52% |
| SECTOR GAMMA AS | 721,058 | $53,243,000 | 8.85% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,747,061 | $202,843,000 | 5.38% |
| Veritas Asset Management LLP | 8,852,005 | $653,632,000 | 5.36% |
| Knowledge Leaders Capital, LLC | 79,384 | $5,862,000 | 4.39% |
| HealthCor Management, L.P. | 1,800,000 | $132,912,000 | 4.22% |
| Progressive Investment Management Corp | 79,282 | $5,854,000 | 3.78% |
| 13D Management LLC | 200,318 | $14,791,000 | 3.77% |
| ARGENT CAPITAL MANAGEMENT LLC | 1,288,236 | $95,123,000 | 3.42% |
| Chiron Investment Management, LLC | 612,787 | $45,248,000 | 3.12% |